Jubilant Pharmova Ltd
NSE:JUBLPHARMA
Intrinsic Value
Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. [ Read More ]
The intrinsic value of one
JUBLPHARMA
stock under the Base Case scenario is
507.9
INR.
Compared to the current market price of 719.65 INR,
Jubilant Pharmova Ltd
is
Overvalued by 29%.
Jubilant Pharmova Ltd's market capitalization is 114B INR.
JUBLPHARMA stock price is 719.65 INR.
JUBLPHARMA stock (507.9 INR) is 29% less than its price (719.65 INR).
JUBLPHARMA stock (384.06 INR) is 47% less than its price (719.65 INR). Open DCF Valuation
JUBLPHARMA stock (631.75 INR) is 12% less than its price (719.65 INR). Open Relative Valuation
JUBLPHARMA has upside potential of 9% compared to the average analyst price target.
Open Wall St Estimates
JUBLPHARMA has positive Operating Income for the last twelve months.
JUBLPHARMA's Revenue has grown by 8% over the past 12 months.
JUBLPHARMA's Revenue has been growing by 3% per year for the last 3 years.
JUBLPHARMA has positive Net Income for the last twelve months.
JUBLPHARMA has positive three-year average ROE (Return on Equity): 7%. The company is efficient at transforming stockholders' equity into net income.
JUBLPHARMA's ROIC (Return on Invested Capital) has decreased in the last 3 years from 9% to 1%.
JUBLPHARMA's Altman Z-Score is equal to 2.27.
JUBLPHARMA's ROIC (Return on Invested Capital) for the past 12 months is very low and is equal to 1%.
JUBLPHARMA's ROE (Return on Equity) for the past 12 months is very low and is equal to 1%.
JUBLPHARMA has positive Free Cash Flow for the last twelve months.
JUBLPHARMA has positive three-year average ROIC (Return on Invested Capital): 5%. The company is efficient at using invested capital to generate operating income.
JUBLPHARMA's ROE (Return on Equity) has significantly decreased in the last 3 years from 16% to 1%.
JUBLPHARMA's long-term assets (114B INR) exceed its long-term liabilties (60B INR).
JUBLPHARMA's short-term assets (36B INR) exceed its short-term liabilties (18B INR).
JUBLPHARMA has positive Net Debt. This means that the company has more debt (34B INR) than cash and short-term investments (11B INR).
JUBLPHARMA's D/E (Debt to Equity) is very low and is equal to 0.62.
JUBLPHARMA has positive Gross Profit for the last twelve months.
JUBLPHARMA generates enough operating income (3B INR) to cover interest payments on its debt (2B INR).
Valuation Backtest
Jubilant Pharmova Ltd
Run backtest to discover the historical profit from buying and selling
JUBLPHARMA
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Jubilant Pharmova Ltd
Balance Sheet Decomposition
Jubilant Pharmova Ltd
| Current Assets | 36.1B |
| Cash & Short-Term Investments | 11B |
| Receivables | 9.3B |
| Other Current Assets | 15.8B |
| Non-Current Assets | 77.9B |
| Long-Term Investments | 2.9B |
| PP&E | 36.2B |
| Intangibles | 34.7B |
| Other Non-Current Assets | 4.2B |
| Current Liabilities | 17.9B |
| Accounts Payable | 9.2B |
| Other Current Liabilities | 8.7B |
| Non-Current Liabilities | 42B |
| Long-Term Debt | 33.7B |
| Other Non-Current Liabilities | 8.3B |
Earnings Waterfall
Jubilant Pharmova Ltd
|
Revenue
|
66.2B
INR
|
|
Cost of Revenue
|
-21.4B
INR
|
|
Gross Profit
|
44.8B
INR
|
|
Operating Expenses
|
-41.8B
INR
|
|
Operating Income
|
3B
INR
|
|
Other Expenses
|
-2.6B
INR
|
|
Net Income
|
378.6m
INR
|
Free Cash Flow Analysis
Jubilant Pharmova Ltd
| INR | |
| Free Cash Flow | INR |
JUBLPHARMA Profitability Score
Profitability Due Diligence
Jubilant Pharmova Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
Score
Jubilant Pharmova Ltd's profitability score is 49/100. The higher the profitability score, the more profitable the company is.
JUBLPHARMA Solvency Score
Solvency Due Diligence
Jubilant Pharmova Ltd's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Score
Jubilant Pharmova Ltd's solvency score is 43/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JUBLPHARMA Price Targets Summary
Jubilant Pharmova Ltd
According to Wall Street analysts, the average 1-year price target for
JUBLPHARMA
is 787.95 INR
with a low forecast of 374.71 INR and a high forecast of 1 232.7 INR.
Shareholder Return
JUBLPHARMA Price
Jubilant Pharmova Ltd
| Average Annual Return | 0.26% |
| Standard Deviation of Annual Returns | 45.33% |
| Max Drawdown | -73% |
| Market Capitalization | 113.7B INR |
| Shares Outstanding | 158 351 008 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Jubilant Pharmova Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. The company is headquartered in Noida, Uttar Pradesh. The firm's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one
JUBLPHARMA
stock under the Base Case scenario is
507.9
INR.
Compared to the current market price of 719.65 INR,
Jubilant Pharmova Ltd
is
Overvalued by 29%.
You don't have any saved screeners yet
